

Substitute for form 1449A/PTO

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

<i>Application Number</i>	10/726,168
<i>Filing Date</i>	December 2, 2003
<i>First Named Inventor</i>	M. Abou-Gharbia
<i>Art Unit</i>	1617
<i>Examiner Name</i>	S. Wang
<i>Attorney Docket Number</i>	AM100146C2/WYTH0107-100

[illegible][illegible]

Examiner Signature	<i>S. Wang</i>	Date Considered	8/14/07
-----------------------	----------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/726,168		
		Filing Date	December 2, 2003		
		First Named Inventor	M. Abou-Gharbia		
		Art Unit	1617		
		Examiner Name	S. Wang		
Sheet	2	of	2	Attorney Docket Number	AM100146C2WYTH0107-100

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SW	5	Singh, A. et al., "Antidepressant-like Activity of Compounds with Varying Efficacy at 5-HT _{1A} Receptors", <i>Neuropharmacology</i> , 32; 331-340, 1993.	

Examiner Signature	S. Wang	Date Considered	8/14/07
-----------------------	---------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/726168
Filing Date	12/02/2003
First Named Inventor	Magid A. Abou-Gharbia
Art Unit	1617
Examiner Name	Shengjun Wang
Attorney Docket Number	WYTH0107-100/AM100146US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SW	1	Nakata et al., "Role of hippocampal serotonergic neurons in ischemic neuronal death," <i>Behavioural Brain Research</i> (1997) 83(1-2):217-220.	
SW	2	"Sources of Glutamate in Cerebral Ischemia," www.med.uio.no/imb/anatomi/gruppe_3/ischemia.htm , July 1995, p. 1-2	
SW	3	Prehn et al., "Effects of serotonergic drugs in experimental brain ischemia: evidence for a protective role of serotonin in cerebral ischemia" <i>Brain Research</i> (1993) 630(1-2):10-20	

Examiner
Signature

S. Wang

Date
Considered

8/14/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	Not yet assigned
				Filing Date	December 2, 2003
				First Named Inventor	Magid A. Abou-Gharbia
				Group Art Unit	1617
				Examiner Name	R. Travers
Sheet	1	of	1	Attorney Docket Number	AM100146 C2

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If known)			
SW	1.	5,380,725		M. Abou-Gharbia et al.	01-10-1995	
	2.	5,441,961		M.L. Cohen et al.	08-15-1995	
	3.	5,482,940		M. Abou-Gharbia et al.	01-09-1996	
	4.	5,691,324		Renven Sandyk	11-25-1997	
	5.	5,739,146		M.L. Cohen et al.	04-14-1998	
	6.	5,877,173		J.W. Olney et al.	03-02-1999	
	7.	5,902,815		J.W. Olney et al.	05-11-1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	8.	DE	4 138 756		Kerstin Bode-Greuel	05-27-1993		<input type="checkbox"/>

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T	
SW	9.	W. HOLT, Neuroprotection in CNS Diseases, 1997, 87-119, Marcel Dekker, Inc., NY	<input type="checkbox"/>	
	10.	B. ENGELSEN, Neurotoxicity of Excitatory Amino-Acids, 1990, 311-332, Raven Press, NY	<input type="checkbox"/>	
	11.	INCE et al., Rev. Contemp. Pharmacother., 1997, 195-212, 8	<input type="checkbox"/>	
	12.	B. MELDRUM et al., Prog. Brain Res., 1998, 441-458	<input type="checkbox"/>	
	13.	KOROSHETZ et al., Sci., 1996, 227-233, 17	<input type="checkbox"/>	
	14.	C.D.R. DUNN, Scrips Reports, 1995, 61-90 and 149-159, PJB Publications, Richmond	<input type="checkbox"/>	
	15.	J.E. ARROWSMITH et al., Stroke, 1998, 2357-2362, 29	<input type="checkbox"/>	
	16.	J. DeVRY, Psychopharmacology, 1995, 1-26, 121	<input type="checkbox"/>	
	17.	S. MATSUYAMA, Brain Res., 1996, 175-180, 728	<input type="checkbox"/>	
	18.	J. DeVRY, Drugs of the Future, 1997, 341-349, 22	<input type="checkbox"/>	
	19.	BODE-GREUEL, Pharm. of Cerebral Ischemia, 1990, 485-491	<input type="checkbox"/>	
	20.	B. LIN et al., Stroke, 1990, 1734-1739, 21	<input type="checkbox"/>	
	21.	H. NAKAYUAMA et al., Neurology, 1989, 1667-1673, 38	<input type="checkbox"/>	
	22.	J. KRIEGLSTEIN et al., Eur. Neurology, 1989, 224-228, 29	<input type="checkbox"/>	
	23.	H. FUJIKURA et al., Brain Res., 1989, 387-390, 494	<input type="checkbox"/>	
	24.	COYLE, Harvard Rev. Psychiatry, 1996, 241-253, 3(5)	<input type="checkbox"/>	
	25.	SMITH et al., Pharmacol. Biochem. Behavior, 1986, 1513-1519, 24	<input type="checkbox"/>	
	26.	LAZARENO et al., Br. J. Pharmacol., 1993, 1120-27, 109	<input type="checkbox"/>	
	27.	LUCKI et al., J. Pharma. and Exp. Ther., 1983, 133-39, 228(1)	<input type="checkbox"/>	
	28.	DJALI et al., Soc. for Neuroscience Abs., 2000, 857.9, 26(1-2)	<input type="checkbox"/>	
	29.	J. MOYER et al., Soc. for Neuroscience Abs., 1991, 1603, 17(1-2)	<input type="checkbox"/>	
	30.	Drugs of the Future, Abs., 1992, Wy 50324, 17(11)	<input type="checkbox"/>	
	31.	Mark S. KLEVEN et al., J. Pharmacol. Exp. Ther., 1996, 388-97, 276(2)	<input type="checkbox"/>	
	32.	M. ABOU-GHARBIA et al., J. Med. Chem., 1999, 5077-5094, 42	<input type="checkbox"/>	
	33.	G.W. BIELENBERG et al., Eur. J. Pharmacol., 1990, 1953-54, 183	<input type="checkbox"/>	

Examiner Signature	<i>S. Wang</i>	Date Considered	8/14/07
--------------------	----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.